The designation was granted to Revive Therapeutics, a company that specializes in cannabis-based pharmaceuticals.
Both chest tube placement and needle aspiration were considered acceptable treatments for primary spontaneous pneumothorax.
ALIS has previously been designated orphan drug status, breakthrough therapy status and a Qualified Infectious Disease Product.
Use of prophylactic antimicrobial therapy was not associated with a reduction in mortality or transfer to critical care compared with patients managed with supportive care only.
Treatment with a small pigtail catheter may shorten the drainage duration and length of hospital stay in patients with spontaneous pneumothorax.
A new cystic fibrosis transmembrane conductance regulator modulator treatment has been approved by the FDA for use in patients aged 12 years and older.
Enteral nutritional support was not clinically superior to parenteral nutritional support in critically ill patients receiving mechanical ventilation.
Adults with cardiac arrest have better outcomes with continuous compressions with asynchronous ventilations or compression-to-ventilation ratios of 30:2.